Flatiron Health

Hear from experts at Exact Sciences, Bristol Myers Squibb, Exigent Research Network, and Flatiron Health on the ways pragmatic design in #clinicaltrials is driving efficiency while generating high-quality evidence. Join us on Dec 4th at 12 pm to walk away with: - Why we need to overcome the operational burden of traditional clinical trials - How a pragmatic study design can enable more research without adding burden - How streamlined trial design and data capture may improve trial access and representativeness Secure your spot & ask our panel of experts your questions directly. Register now: https://lnkd.in/e_qqa2tn

Flatiron is uniquely positioned to apply #AI and #machinelearning to advance point of care, #clinicalresearch, and #realworldevidence generation. From extracting clinically relevant information from the EHR, to understanding how treatments work in diverse populations, to surfacing eligible patients for #clinicaltrials, Flatiron has pioneered the use of ML in real-world evidence generation to help us deliver on our mission to improve and extend lives by learning form every person with cancer. ?? Hear from Flatiron Chief of AI, Will Shapiro on a recent episode of the 'What's up with Tech?' podcast.

Cancer care for patients with advanced non-small cell lung cancer (aNSCLC) has transformed into a personalized, precision approach with several targeted therapies approved by the FDA enabled via biomarker testing. While there has been an increase in biomarker testing in clinical practices, rates of timely and adequate testing remain suboptimal, leaving eligible patients without targeted therapy options. One of Flatiron's #1000publications, completed in collaboration with Genentech, Foundation Medicine and Flatiron Health cancer clinics OneOncology and West Cancer Center & Research Institute, showed persistent racial/ethnic inequities in biomarker testing, highlighting non-Latinx Black and Latinx patients being consistently underserved, with an approximately 8% lower next generation sequencing biomarker testing rate versus non-Latinx White. The study improved understanding of the factors contributing to biomarker testing inequities for patients with aNSCLC, providing recommendations to improve testing equity and the information needed to design targeted interventions and policies to improve equity and outcomes for all patients. This #LungCancerAwarnessMonth, discover more from Flatiron's #1000publications generating critical evidence for patients with lung cancer: https://lnkd.in/eY_jZqb4

Flatiron Health is presenting seven abstracts at this year’s #ASH24 that leverage our #realworlddata at scale to improve our understanding of current therapies and identify treatment gaps for patients with #hematologicmalignancies. Check out what Flatiron experts will be onsite and schedule time with them to learn more: https://spkl.io/6045fnHpP

Join a panel of experts from Exact Sciences, Bristol Myers Squibb, and Exigent Research Network, moderated by Flatiron Health to gain insight into perspectives and experiences with pragmatic clinical trial design. ??? Moderated by Ivy Altomare MD, Flatiron Health ?? Wednesday, December 4th from 12-1 PM ET Secure your spot & ask our panel of experts your questions directly. Register now: https://spkl.io/6043fn1Sc

ANNOUNCED TODAY: Flatiron Health and Willowglade Technologies to partner to bring Willowglade’s Unified Digital Patient Experience? Platform to practices using Flatiron’s OncoEMR? through Flatiron’s Trusted Partner Network. Willowglade’s platform, together with OncoEMR, positions practices to spend more time with patients and provide a better care experience for clinicians and their patients. Learn more: https://spkl.io/6045fVfuh

Flatiron Health is presenting five abstracts at this year’s #ISPOREurope that leverage our high-quality, multinational oncology data assets and novel methodological approaches, unlocking critical evidence to accelerate access to cancer treatments worldwide. Check out what Flatiron experts will be onsite and schedule time with them to learn more: https://lnkd.in/eSXMzi8X

ANNOUNCED TODAY: Flatiron Health to present seven abstracts at #ASH24. Through our research accepted at this year’s conference, Flatiron’s scientists and collaborators are using our #RWD at scale to improve our understanding of current therapies & identify treatment gaps for patients with hematologic malignancies. Learn more: https://spkl.io/6044fpLfI

With 230,000 new cases of lung cancer a year in the United States, it remains one of the most active areas of #cancerresearch today. This #LungCancerAwarenessMonth, we’re highlighting one of Flatiron Health’s #1000Publications which used #RWD to define timelines for progression-free NSCLC patients to discontinue immunotherapy treatments after two years without compromising survival benefits. Using #RWD, this research has the potential for direct impact on the quality of life for patients with NSCLC. If you’re interested in reading the full study, click here: https://spkl.io/6045fplaP

Flatiron’s Neal Meropol spoke on an insightful panel at the Friends of Cancer Research Annual Meeting earlier today building off a recently published white paper. The conversation revealed a few key insights, including: ?? Incorporating pragmatic elements into #clinicaltrial designs can enhance generalizability and efficiency ?? Opportunities for pragmatic trial elements exist broadly, however, identifying appropriate pragmatic elements based on the research question, trial objectives, and clinical setting is critical ?? Tech like #AI-enabled trial matching, EHR-to-EDC connectors, and more are viable pragmatic elements that can lower the burden and reduce the complexity of clinical trials Read the full white paper to learn more: https://spkl.io/6046fpWaA